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doi:10.1016/j.ejvs.2010.12.018Abstract Objectives: To examine the accuracy of previously developed prediction models of
treadmill walking performance in patients with intermittent claudication (IC) due to peripheral
arterial disease (PAD); and to examine the accuracy of new prediction models.
Design: Analysis of data collected in a previous randomised clinical trial.
Materials: Ninety-three assessments of 28 patients diagnosed with IC due to PAD.
Methods: Patients undertook routine clinical assessments, quality of life (QOL) questionnaires
and treadmill walking tests. Walking performance and estimates based on prediction models
were compared via paired t-tests or Wilcoxon Rank Sum tests. Stepwise linear regression
generated models to predict walking performance from clinical measures and QOL responses.
Accuracy was determined as the absolute error between model estimates and patient results.
Results: Walking performance was significantly underestimated (35e71% error) by previously
developed prediction models. Models developed in the current study identified QOL responses
as the most significant predictors of current walking performance but these models still
resulted in substantial errors (19e84%).
Conclusions: Previously published predictors of walking performance significantly underesti-
mated patient’s ability in practise. Predictions based upon clinical measurements and QOL
responses were developed however, their accuracy was also limited. Further research is
needed regarding walking performance prediction to assist clinicians with assessment of PAD
severity and treatment effectiveness.
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13 14Peripheral arterial disease (PAD) affectsw10% of older male
Australians with the incidence increasing progressively
(i.e. 0.85% per annum).1 Patients typically experience
intermittent claudication (IC) that impacts on health-
related quality of life (QOL) and walking ability.2 Medical
screening for PAD typically involves clinical assessments of
symptoms, ankleebrachial pressure index (ABI) and lower
limb peripheral pulses.3 Walking ability and QOL are the
main functional assessments used to assess the impact of IC
on the individual patient.2,4e6 Assessment of walking ability
from history alone and patient self reports have been
demonstrated to be inaccurate7,8 and thus treadmill tests
have been developed as less subjective measures of walking
impairment.8,9 Such tests are not always feasible in indi-
vidual patients or clinical settings due to lack of equipment
and qualified exercise personnel. Models to predict the
effect of PAD on walking ability and functional capacity
(e.g. peak aerobic capacity, _VO2peak) have been suggested as
simple tools to assess the impact of PAD on the individual
patient. Previously, ABI, laterality of claudication pain,
gender, body mass index and current smoking status were
reported to predict maximal and pain-free treadmill walking
ability (rZ 0.73e0.82) for PAD patients.8,9 Similarly,
a prediction model using maximal treadmill walking time,
maximal heart rate and body mass index was developed to
predict _VO2peak in PAD patients.
10 Although potentially useful
for clinicians, these prior prediction models8e10 (Table 1)
have not been validated in multiple populations nor has the
error associated with these models been examined in detail.
Compared to prior reports,8,10 prediction models based
on routine clinical measurements including QOL responses
may be more applicable and accurate for PAD patients. For
example, QOL is increasingly being assessed in patients
with PAD4,11 using either a generic QOL questionnaire such
as the Short-Form 36 (SF-36)4,11 or a disease specific ques-
tionnaire like the Intermittent Claudication Questionnaire
(ICQ).12 Both the ICQ and SF-36 are simple, self-admini-
stered questionnaires that provide valid and reliable indi-
cators of patient QOL.11,12 To date, no study has examined
the use of QOL responses with other routine clinical
measures in the prediction of walking performance for PAD
patients. Nicolai and colleagues concluded that changes in
the Walking Impairment Questionnaire (WIQ) could be used
as surrogates to treadmill testing as WIQ changes correlatedTable 1 Summary of previously reported prediction models inc
standard estimate of the error (SEE) for pain-free (PFWD) and ma
( _VO2peak).
Prediction model
PFWD (m) Based on worst ABI, gender, BMI and c
Based on ABI, laterality of claudication
MWD (m)8 Based on worst ABI, gender, BMI and c
Based on ABI, laterality of claudication
_VO2peak
(ml kg1 min1)
Based on MWD, maximal heart rate du
and BMI10
ABI; ankleebrachial pressure index, BMI: body mass index.therapy. Likewise, Kruidenier and colleagues reported
that patient’s preferred walking distance was highly
correlated (0.41e0.57) with five of the nine sub-domains of
the RAND-36 health questionnaire, a variation of the SF-36.
These studies provide impetus for the development of
assessment tools based on QOL responses to assess PAD
severity, treatment effectiveness, and functional capacity.
The aims of the current study were: Firstly, to examine the
accuracy of previously developed prediction models of tread-
mill walking performance in patients with IC; and secondly, to
examine the validity and accuracy of newpredictionmodels of
walking performance that include routine clinical measure-
ments and QOL questionnaire responses.
Materials and Methods
Participants
As part of a previous randomised clinical trial where assess-
ments were conducted every 3e12 months over a 1-year
period,15 all patients with recordings of clinical measure-
ments, QOL, treadmill walking ability and functional capacity
(i.e. _VO2peak) were included in the current study. Each
assessment was considered as a separate entity as all data
were collected at each time point. Data from 93 assessments
of 28 patients with IC due to PAD were included in this study
(i.e. 1 assessment of 5 patients, 2 assessments of 2 patients,
4 assessments of 21 patients). As previously described,15 PAD
wasdiagnosedby theabsenceof lower limbperipheralpulses,
lower limbartery stenosis,orocclusiononduplexor computer
tomographic angiography and ABI < 0.9. Patients completed
a general health questionnaire for identification of medica-
tions and co-morbiditieswith patient characteristics shown in
Table 2. All patients provided informed written consent and
all procedures were approved by the local university and
health district Research Ethics Committees. The study was
conducted in accordance with the principles outlined in the
Declaration of Helsinki.
Assessments
Patients arrived at the laboratory in the morning in a fasted
state. All patients were asked to refrain from physical
activity in the 24-h preceding assessments and to not take
medications on the morning of assessments. Patient heightluding multiple correlation coefficient (r), variance (r2) and
ximal walking distance (MWD), and peak oxygen consumption
r (r2) SEE
urrent smoking status8 0.73 (0.53) 56
pain and gender9 0.74 (0.55) 111
urrent smoking status8 0.82 (0.67) 75
pain and gender9 0.76 (0.58) 138
ring a treadmill walking test, 0.71 (0.50) 2.02
Table 2 Clinical characteristics and quality of life
indicators for patients.
Patients
Age (y) 69.0 7.6
Height (cm) 165.7 8.6
Mass (kg) 77.8 16.7
Body fat (%) 33.0 7.5
Male 50 (54)
ABI e left 0.67 0.21
ABI e right 0.70 0.23
ABI e best 0.79 0.23
ABI e worst 0.58 0.16
Current smoker 24 (26)
Former smoker 57 (83)
Diabetes 21 (23)
Hypertension 40 (43)
MI 27 (29)
Stroke 18 (19)
Angina 22 (24)
Cancer 16 (17)
Beta-blocker 19 (21)
ACEI 23 (26)
Statin 44 (49)
CCB 19 (21)
Antiplatelet 58 (65)
Ang-II blocker 21 (24)
ICQ 41.8 17.1
SF-36 PF 34.6 9.2
SF-36 RP 44.2 7.8
SF-36 BP 39.3 8.2
SF-36 GH 42.4 11.5
SF-36 V 42.6 11.6
SF-36 SF 46.4 11.9
SF-36 RE 45.1 9.6
SF-36 MH 48.1 13.8
SF-36 PCS 36.9 9.3
SF-36 MCS 49.7 13.7
Values are mean SD or number (%), MI: prior myocardial
infarction, ACEI: angiotensin converting enzyme inhibitor,
CCB: calcium channel blocker, Ang-II blocker: angiotensin II
receptor blocker, ICQ: Intermittent Claudication Questionnaire
score, SF-36: scores for physical functioning (PF), role-physical
(RP), bodily pain (BP), general health (GH), vitality (V), social
functioning (SF), role-emotional (RE), mental health (MH),
physical component summary (PCS) and mental component
summary (MCS) for Short-Form 36 questionnaire.
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Germany) while body mass and body fat percentage were
determined via bioelectrical impedance scales (TANITA TBF
521, TANITA Corporation of America, Arlington Heights,
ILL). Patients then completed the ICQ and SF-36 question-
naires followed by assessment of ABI and walking ability.
Quality of life
The 16 item ICQ and 11 item SF-36 (v2) questionnaires were
self-administered by each patient.11,12 Each ICQ item wasrated on a 5 or 6 point scale by patients with responses
summed and transformed to a final score between 0 (best
possible health state) and 100 (worst possible health
state).12 The SF-36 items were rated on a 3e6 point scale
by patients.11 As described previously,11 item responses
were recoded and summed for the health domain scores of
physical functioning (PF), role-physical (RP), bodily pain
(BP), general health (GH), vitality (V), social functioning
(SF), role-emotional (RE) and mental health (MH). Scores
were then transformed using Australian SF-36 population
norms16 to calculate norm-based (i.e. mean of 50, standard
deviation of 10) scores with 0 (worst) and 100 (best) being
the lowest and highest possible scores. Summary measures
of physical (PCS) and mental components (MCS) were also
calculated based on the 8 health domain scores.11
ABI and walking ability
Following a 15-min supine rest, ABI was assessed in both
legs as previously described.15 Patients were then con-
nected to a metabolic analysis system (POWERLAB 8M,
ADInstruments Pty Ltd, Bella Vista, Australia) for the
continuous monitoring of heart rate (Lead II) and respira-
tion during a graded walking test on a motorised treadmill.
The walking test commenced at 3.2 km h1 (0% incline) that
increased by 2% every 2 min until voluntary exhaustion or
a maximum time of 25 min.5 Pain-free walking distance
(PFWD) and maximal walking distance (MWD) were recor-
ded during the walking test.15 All respiratory data were
recorded using Chart (ADInstruments, Bella Vista,
Australia) at a sampling rate of 1 kHz and analysed offline
for oxygen consumption ( _VO2) every 15 s.
15 Peak oxygen
consumption ( _VO2peak) was determined as the greatest 15-s
value at MWD attainment and deemed an indicator of
functional capacity for PAD patients.17
Data and statistical analysis
Data were analysed using the Statistical Package for the
Social Sciences (SPSS v17, SPSS Inc., Chicago, ILL).
Comparisons for MWD, PFWD and _VO2peak between patient
results and estimates using previously developed prediction
models (Table 1)8,10 were analysed using paired t-tests or
Wilcoxon Signed Ranks Tests, where appropriate. Accuracy
of the prior prediction models (Table 1)8,10 for the current
patient cohort was further examined by the:
1) Absolute error18 (%)Z (absolute difference between
predicted and actual)/actual 100;
2) Proportion of predicted values within 10%, 10e25% and
>25% of the actual patient result.
Stepwise linear regression was conducted to generate
regression models for all patients to predict MWD, PFWD
and _VO2peak from the independent variables of: age; gender
(maleZ 1; femaleZ 0); height; mass; body fat
percentage; current and former smoking status (yesZ 1,
noZ 2); medications (i.e. beta blockers, ACE inhibitors,
statins, calcium channel blockers, antiplatelet inhibitors,
angiotensin II receptor blockers; yesZ 1, noZ 2); prior
incidence of co-morbidities (diabetes mellitus, hyperten-
sion, myocardial infarction, stroke, lung disease, angina,
cancer; yesZ 1, noZ 2); ABI of the left and right legs;
514 A.S. Leicht et al.worst and best ABI; ICQ and SF-36 individual item
responses; ICQ total score; and SF-36 health domain and
component summary values. Accuracy of the newly devel-
oped regression models was determined as described
above. Comparisons of proportions in the three error
categories between the prior and current prediction models
were conducted using Chi-squared tests. The level of
significance was set at P < .05. Data presented as
mean SD unless otherwise stated.
Results
Quality of life responses for the ICQ and SF-36 question-
naires are shown in Table 2 with 73.9% and 45.7% of patients
exhibiting below average PCS and MCS, respectively,
compared to the age-sex matched general population.
Actual compared to estimated values from
previously developed prediction models
Patients demonstrated significantly greater PFWD, MWD
and _VO2peak compared to estimates based on previously
published models (Table 3). Accuracy of these prediction
models was poor with substantial absolute errors for PFWD
(71.2%  61.2%), MWD (65.9%  62.9%) and _VO2peak
(35.6%  23.7%). Further, w70e80% of patient estimates
for PFWD, MWD and _VO2peak were greater than 25% different
to actual patient results (see Fig. 1).
New prediction models
Stepwise regression analyses identified variables such as
ICQ and SF-36 responses, ABI, height, medication use and
co-morbidities as independent predictors of PFWD, MWD
and _VO2peak (Table 4). Prediction models incorporating both
clinical measures and QOL responses resulted in the
greatest multiple correlation coefficients and smallest
estimate of the error (Table 4). Using these new prediction
models, the absolute error for PFWD (84.3%  93.9%) was
similar to that using prior published models. Compared to
the prior published models, the new models resulted in
significantly lower absolute errors for MWD (59.3%  63.8%,
P < .05) and _VO2peak (19.7%  20.5%, P < .001), and
a greater proportion of absolute errors within the 10e25%
and <10% for MWD and _VO2peak, respectively (Fig. 1).
Discussion
The current study demonstrated that walking ability and
functional capacity for PAD patients with IC wereTable 3 Walking performance estimates based on prior and curr
Estimate based on
prior studies8,10
PFWD (m) 132 46
MWD (m) 289 78
_VO2peak(ml kg
1 min1) 13.1 2.4
Values are mean SD, PFWD: pain-free walking distance, MWD: maxim
***P < .001 vs. estimate based on prior studies.significantly underestimated using prior published predic-
tion models. Inclusion of generic and specific QOL responses
with other clinical measurements resulted in the develop-
ment of new prediction models for walking performance
that were more accurate (i.e. reduced absolute error) for
MWD and _VO2peak than previously published models in this
patient group. Despite exhibiting greater accuracy, the new
models were still limited with substantial mean absolute
errors of 19e84%, depending on the variable (i.e. PFWD,
MWD or _VO2peak). Further research is needed to improve the
accuracy and validity of prediction models of treadmill
walking performance in PAD patients if such models are to
be of clinical value.
The most important finding of the current study was that
the use of published prediction models8,10 significantly
underestimated PFWD, MWD and _VO2peak for patients with
IC. The mean absolute error associated with these esti-
mates was substantial (i.e. 35e71% depending on the vari-
able). This level of inaccuracy was surprising as these prior
models had been developed and then cross-validated in PAD
patients with modest standard errors of estimate (56e75 m
and 2.0 ml kg1 min1) and coefficients of variation
(17.8e23%). Differences in patient population may account
for the disparate results with the prior study dominated by
males8 and the present study consisting of approximately
equal numbers of male and female patients. Walking
performance prediction may be dependent on the patient
population with current prediction models insufficiently
accurate for widespread clinical use. Alternatively, the
accuracy of current prediction models may be limited by
the variables assessed (i.e. clinical variables only). Subse-
quently, we examined new prediction models based on
clinical measures and QOL indicators as QOL is an important
contributor to patient walking ability.13,14
In the current study, QOL responses, indicated by the
first parameter in each prediction equation, were the
greatest independent predictors of walking performance
for patients Interestingly, worst ABI was identified as
a significant predictor for MWD only, but was of secondary
predictive power to QOL responses. Previously Gardner
and colleagues8,9 reported that resting ABI was the most
significant predictor of walking ability for PAD patients.
The poorer contribution of ABI to predict walking ability in
the current study cannot be explained by PAD severity as
patients exhibited similar PFWD and MWD to prior
studies8,9 despite lower ABI. ABI may be of limited benefit
for predicting walking ability for PAD patients. The lack of
association between ABI and improved walking ability
following exercise training15,19 and increased mortality
risk in PAD patients with poor walking ability but normal
ABI20 provides further support that walking ability may beent prediction models and actual results for current patients.
Current patient result Estimate from current
prediction models
202 183** 200 131
416 271*** 410 201
19.2 6.1*** 19.8 5.5
al walking distance, _VO2peak: peak oxygen consumption, **P < .01,
Figure 1 Distribution of absolute errors when applying
prior8,10 (-) and current (,) prediction models for estimating
patients actual pain-free walking distance (A), maximal
walking distance (B) and peak oxygen consumption (C). *P< .05
vs. prior prediction models for the absolute error category.
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responses. Further, QOL responses may be more important
than other reported predictors such as gender.8,9 Gender
was not identified as a significant predictor ofwalking ability
in the current study unlike someprevious reports.21,22 Based
on the current study, QOL appears as an important predictor
of walking ability for patients with IC.
To our knowledge, QOL has not been examined previ-
ously as a predictor of walking ability for PAD patients
although significant correlations have been reported
between QOL (e.g. SF-36, WIQ, RAND-36) and walking
ability in PAD patients.2,13,14 Improvements in walking
ability and QOL following regular exercise training for PADpatients13,23,24 indicated a strong relationship between QOL
and walking ability supporting the role of QOL in the
prediction of walking performance. In the current study,
the most important predictors of PFWD and MWD were item
2 and item 3 g of the SF-36 that required patients to indi-
cate their current health compared to 6 months ago and the
level of limitation that their current health had on their
ability to walk more than 1 km. These results indicate that
overall health consisting of physical, mental and emotional
factors and its’ impact on walking ability over large
distances may be more indicative of patient ability
compared to patient self report and case history.7 Previ-
ously, self reported walking distances, in terms of ½ blocks
(45.7 m) underestimated the actual walking ability of PAD
patients.8 Therefore, patient-identified limitations of
walking ability over large distances (e.g. 1 km) may be
better indicators of real PFWD and MWD compared to
smaller walking distances8 or self reports7 as they require
patients to assess ability in significant terms. Additionally,
the inclusion of these QOL items within a framework of
other questions may also mask the intent thereby allowing
patients to more confidently and accurately estimate
walking ability compared to a single question such as “How
far can you walk without symptoms?” Regardless, the
current results indicate that a simple QOL assessment can
simultaneously provide important information about
patient QOL and walking ability estimation. This dual
function of QOL assessment may minimise the need for
specialist personnel and equipment for walking estimates
while maximising patient consultation time for effective
assessment and treatment.
Despite the identification of QOL responses as significant
predictors in the current study, the new prediction models
resulted in significant absolute errors, albeit lower errors
for MWD and _VO2peak than previous models.
8,10 Therefore,
the clinical use of these models cannot be recommended.
Recently, other investigators have suggested similar
caution with new prediction models after identifying MWD
predictors in IC patients after supervised training that were
inaccurate (i.e. <34% of estimates within patient actual
results).25 Together, the current and previous results25
indicate a need for greater development of simple
models for the prediction of walking performance in PAD
patients.
An interesting aspect to the current study was that the
new prediction model for _VO2peak resulted in a significant
reduction in the absolute error associated with estimation
and more estimates within 10% of the actual _VO2peak
exhibited by PAD patients. In contrast, estimates based on
a prior model10 were on average 35% different to the
patient result with a large proportion of estimates (w70%)
greater than 25% different to actual values. This prior
prediction model identified _VO2peak based on maximal
walking time, maximal heart rate and BMI,10 measures that
still require specialised equipment and personnel to
conduct the test. On the contrary, the current study
developed a new predictive model that more accurately
estimated _VO2peak for PAD patients without the need for
specialised exercise equipment or personnel and therefore
greater applicability to clinical settings. However, we
recommend that further research is needed to develop
more robust models.
Table 4 Newly developed prediction models, multiple correlation coefficient (r), variance (r2) and standard estimate of the
error (SEE) for pain-free (PFWD) and maximal walking distance (MWD), and peak oxygen consumption ( _VO2peak).
Prediction model*** r (r2) SEE
PFWD (m) Z 545.106  (65.992  Q2)þ (159.705  Q3g) 
(90.02  Q3c)  (33.09  Q5c)  (37.012  ICQ10)
0.71 (0.50) 134
MWD (m) Z1911.33þ (267.564  Q3g)þ (511.29  worst ABI)þ
(291.335  lung disease presence)þ (6.594  height)
0.71 (0.50) 199
_VO2peak(ml kg
1 min1) Z 36.176  (1.982  ICQ9)  (6.39  beta-blocker use)þ
(3.72  Q3f)  (2.295  antiplatelet use) (2.716  ICQ11) 
(2.574  Q3e)þ (2.242  ICQ15)  (3.933  diabetes presence)þ
(3.097  ACE-inhibitor use)þ (1.137  Q9d)
0.83 (0.68) 3.8
***P < .0001, (e.g. Q2 e response to item 2 in Short-Form 36 questionnaire, ICQ10 e response to item 10 in Intermittent Claudication
Questionnaire).
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It should be noted that the developed predictive models
were limited to patients with IC. The applicability of the
predictive models to PAD patients without IC remains to be
clarified. Further, treadmill walking was used to gauge
patient walking ability with this form of assessment possibly
a poorer indicator of functional ability compared to other
lower intensity based assessments (e.g. 6-min walking
test).26 These other assessment methods may provide
better and simpler indicators of patient ability though
significant correlations between treadmill walking distance
and patients’ level of physical activity27,28 or 6-min walking
distance29 intimate treadmill walking to be indicative of
patient walking ability. Additionally, the new predictive
models were based on small patient numbers with valida-
tion required in larger populations. Lastly, SF-36 health
domain and summary measures were normalised using
Australian based data that may limit the application of the
predictive equations to patients within other countries.
In conclusion, the current study demonstrated that
previously published prediction models of walking perfor-
mance for PAD patients significantly underestimated actual
patient results with substantial errors (average ranging
from 35% to 71% depending on the variable). Combining
both clinical measures and QOL responses resulted in the
development of new prediction models for treadmill
walking performance with better accuracy for MWD and
_VO2peak than previous models. Despite the lower errors of
the new models, further work is required to develop better
models if these tools are to be employed clinically.
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